《大行報告》花旗對匯控(00005.HK)開啟90日上升催化觀察
花旗發表研究報告表示,開展對匯豐控股(00005.HK)為期90日的上升催化觀察期,直至該行於2月下旬發布2023財年業績為止。
該行解釋,開展相關正面觀察,主要基於匯控在2023年期間對利率敏感度指引變化,有理由相信已進行大量對沖,預計在業績發布的同時管理層將會提供更多有關其結構性資金對沖的資訊,有助推動淨資本收益率上升。
花旗又指,加拿大當局上月已批准匯控加拿大業務的剝離計劃,預期對其資本回報潛力有正面作用。基於約55億美元的收益規模及逾40億美元的RWA 釋放,花旗估計匯控的每股21美仙特別股息及回購規模均有可能增加,相應給予「買入」評級,目標價為86.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.